ABCL - AbCellera Biologics GAAP EPS of -$0.14 revenue of $12M
2023-05-04 16:43:39 ET
- AbCellera Biologics press release ( NASDAQ: ABCL ): Q1 GAAP EPS of -$0.14.
- Revenue of $12M.
- Shares -3.8% .
- Total cumulative partnered program starts of 101, up 20% from Q1 2022
- Net loss of $0.14 per share on a basic and diluted basis, compared to net earnings of $0.59 (basic) and $0.54 (diluted) per share in Q1 2022
- Generated a net loss of $40.1 million, compared to net earnings of $168.6 million in Q1 2022.
- Reached a cumulative total of 177 programs under contract with 41 different partners.
For further details see:
AbCellera Biologics GAAP EPS of -$0.14, revenue of $12M